Infrastructure and facilities

• A trial coordination center:  a Phase I trial facility with 12- bed study admission ward and offices

• Bioequivalence center:

A 40+ beds Clinical Facilities with comprehensive participant and staff amenities

Medical Laboratory with a wide range of clinical diagnostic testing services

Bioanalytical Laboratory with state-of-the-art bioanalytical and pharmaceutical instruments

A. AHRI-IVI Collaborating Center

Mission:

Partnering for vaccine R&D and capacity building to improve global public health

B. Clinical Trials Network in Ethiopia (CTN-ET)

Mission:

Coordinating, promoting, and advocating for ethical, efficient, and inclusive clinical trials in Ethiopia through collaboration, capacity building, and policy engagement.

 C. RER-CTO:  

A regional initiative supporting ethics and regulatory excellence and harmonization in clinical trials oversight in sub-Saharan Africa.

Selected Current and Completed (Trials)

• Phase II Marburg virus vaccine trial (2025–2026)
• Bubble CPAP trials for severe childhood pneumonia, phase III to scale-up (2021–2028)
• Probiotic supplementation trials in preterm and small for gestational age infants (2025–2027)
• Telacebec for the treatment of Leprosy ‘TEBULA’: a multi-arm phase II clinical trial, 2025-27
• Serological testing and treatment for plasmodium vivax malaria: a cluster-randomised trial in Ethiopia ‘Pv-Statem’: Real world evidence, 2025-26
• Assessing new paediatric tablets of primaquine as radical cure in Ethiopia ‘APPE’: open label single arm randomized trial: Efficacy in real world evidence, 2024-25
• Clinical investigation to the safety and efficacy of two herbal ointment formulations for the treatment of Tinea corporis/cruris ‘ClinHerb1’: a phase I safety assessment, 2025
• Tafenoquine for vivax malaria radical cure: Feasibility and real-world evidence, 2024-25
• Impact of a cryptosporidiosis point of care test and treat strategy in children with diarrhea: A multicenter stepped-wedge cluster randomized trial ‘Crypto-T&T’: Real world Evidence, 2025-28
• Clinical Validation of AI for diagnosis of skin NTDs ‘SkincAir’, 2025-27
• LeishAccess: Prematurely terminated on futility analysis, 2023-24
• Safety of ointments formulations from essential oils of three medicinal herbs on the healthy human skin: Phase I randomized controlled trial ‘SafeHerb’: 2023-24
• The evaluation of a standard treatment regimen of anti-tuberculosis drugs for patients with MDR-TB (STREAM Stage 1 & 2): 9- and 6-months shorter regimens, 2012-2023 Registration number-ISRCTN78372190
• Effectiveness of Bubble Continuous Positive Airway Pressure (bCPAP) for Treatment of Children aged 1-59 months with Severe Pneumonia in Ethiopia: A Cluster Randomized Controlled Clinical Trial, 2021-23 Registration Number- NCT03870243
• Active case detection and treatment of malaria in pregnancy using LAMP technology: A pragmatic randomized Multi-Center diagnostic outcomes trial ‘LAMPREG TRIAL’, 2021-23 Registration Number- NCT03754322
• An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care ‘SOLIDARITY Trial’: Remdesivir against SOC, 2020-2021
• An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care ‘SOLIDARITY Plus Trial’: Artesunate, Infliximab & Imatinib against SOC, 2022-23
• A phase I assessment of locally assembled mechanical ventillator‘RedVent2021’, 2022-23
• Single dose oral bioequivalence study of Primaquine 15 mg tablet (test product) and Primaquine 15 mg tablet (reference product) in healthy adult human subjects under fasting conditions, 2024-25

Selected & Featured Publications

• Mekonnen Teferi, Banchamlak Tegegne, Claire Kamaliddin, et al. Active case detection using loop-mediated isothermal amplification technology and treatment versus standard of care for malaria in pregnancy in Ethiopia (LAMPREG): a pragmatic randomised diagnostic outcomes trial. The Lancet Primary Care Volume 1, Issue 2100008August 2025.
• Gebre M, Haile K, Duke T, et al. Effectiveness of bubble continuous positive airway pressure for treatment of children aged 1-59 months with severe pneumonia and hypoxaemia in Ethiopia: a pragmatic cluster-randomised controlled trial. Lancet Glob Health. 2024 May;12(5):e804-e814. doi: 10.1016/S2214-109X(24)00032-9. Epub 2024 Mar 21. PMID: 38522443; PMCID: PMC11157334.
• Goodall RL, Nunn AJ, Meredith SK, Bayissa A, Bhatnagar AK, et al. Long-term efficacy and safety of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): extended follow-up of an open-label, multicentre, randomised, non-inferiority trial. Lancet Respir Med. 2024 Dec;12(12):975-987. doi: 10.1016/S2213-2600(24)00186-3. Epub 2024 Oct 1. PMID: 39366400.
• WHO Solidarity Trial Consortium. Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses. Lancet. 2022 May 21;399(10339):1941-1953. doi: 10.1016/S0140-6736(22)00519-0. Epub 2022 May Erratum in: Lancet. 2022 Oct 29;400(10362):1512. doi: 10.1016/S0140-6736(22)01993-6. Erratum in: Lancet. 2024 Jan 13;403(10422):146. doi: 10.1016/S0140-6736(24)00005-9. PMID: 35512728; PMCID: PMC9060606.
• Goodall RL, Meredith SK, Nunn AJ, Bayissa A, et al. Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trial. 2022 Nov 26;400(10366):1858-1868. doi: 10.1016/S0140-6736(22)02078-5. Epub 2022 Nov 8.PMID: 36368336
• Chiang CY, Bern H, Goodall R, et al. Radiographic characteristics of rifampicin-resistant tuberculosis in the STREAM stage 1 trial and their influence on time to culture conversion in the short regimen. BMC Infect Dis. 2024 Jan 30;24(1):144. doi: 10.1186/s12879-024-09039-z.
• Edosa M, Jeon Y, Gedefaw A, et al. Comprehensive Review on the Use of Oral Cholera Vaccine (OCV) in Ethiopia: 2019 to 2023. Clin Infect Dis. 2024 Jul 12;79(Suppl 1):S20-S32. doi: 10.1093/cid/ciae194. PMID: 38996040; PMCID: PMC11244176.
• Achalu DL, Kiltu AB, Teferi M, Mohammed FG, Workneh BD, Beyene KA, Gebretekle GB, Ali EE. Treatment outcomes of standardized injectable shorter regimen for multi-drugs resistant tuberculosis in Ethiopia: a retrospective cohort study. BMC Infect Dis. 2024 Aug 17;24(1):837. doi: 10.1186/s12879-024-09745-8. PMID: 39152383; PMCID: PMC11329998.
• Seralegne YZ, Wangamati CK, Bernabe RDLC, Farsides B, Aseffa A, Zewdie M. Composition and capacity of Institutional Review Boards, and challenges experienced by members in ethics review processes in Addis Ababa, Ethiopia: An exploratory qualitative study. Dev World Bioeth. 2023 Mar;23(1):50-58. doi: 10.1111/dewb.12348. Epub 2022 Mar 5. PMID: 35247023; PMCID: PMC10367191.
• Rosu L, Madan JJ, Tomeny EM, Muniyandi M, et al. STREAM Study Health Economic Evaluation Collaborators. Economic evaluation of shortened, bedaquiline-containing treatment regimens for rifampicin-resistant tuberculosis (STREAM stage 2): a within-trial analysis of a randomised controlled trial. Lancet Glob Health. 2023 Feb;11(2):e265-e277. doi: 10.1016/S2214-109X(22)00498-3. Epub 2022 Dec 21.PMID: 36565704
• Tiemersma EW, Ali I, Alemu A, Avong YK, Duga A, Elagbaje C, Isah A, Kay A, Mmbaga BT, Mmari E, Mwamwitwa K, Nhlabatsi S, Sintayehu K, Arefayne A, Teferi M, Cobelens F, Härmark L.Baseline assessment of pharmacovigilance activities in four sub-Saharan African countries: a perspective on tuberculosis.BMC Health Serv Res. 2021 Oct 8;21(1):1062. doi: 10.1186/s12913-021-07043-6.PMID: 34625085
• Nunn AJ, Phillips PPJ, Meredith SK, et al. A Trial of a Shorter Regimen for Rifampin-Resistant Tuberculosis. N Engl J Med. 2019 Mar 28;380(13):1201-1213. doi: 10.1056/NEJMoa1811867. Epub 2019 Mar 13.PMCID: 30865791
• Abraham Aseffa, Joseph N. Chukwu, et al. Efficacy and Safety of ‘Fixed Dose’ versus ‘Loose’ Drug Regimens for Treatment of Pulmonary Tuberculosis in Two High TB-Burden African Countries: A Randomized Controlled Trial. PLoS One. 2016; 11(6): e0157434. Published online 2016 Jun 20. doi: 10.1371/journal.pone.0157434 PMCID: PMC4913909
• Jemal Hussein, Martha Zewdie, Lawrence Yamuah, Ahmed Bedru, et al. A phase I, open-label trial on the safety and immunogenicity of the adjuvanted tuberculosis subunit vaccine H1/IC31® in people living in a TB-endemic area. Trials. 2018; 19: 24. Published online 2018 Jan 10. doi: 10.1186/s13063-017-2354-0PMCID: PMC5764015
• Sachin N. Desai, Zenebe Akalu, Samuel Teshome, Mekonnen Teferi, et al. ns. Am J Trop Med Hyg. 2015 Sep 2; 93(3): 527–533. doi: 10.4269/ajtmh.14-0683; PMCID: PMC4559691
• Desai SN, Akalu Z, Teferi M, et al. Comparison of immune responses to a killed bivalent whole cell oral cholera vaccine between endemic and less endemic settings. Trop Med Int Health. 2016 Feb;21(2):194-201. doi: 10.1111/tmi.12641. Epub 2015 Dec 18.PMID: 26681205
• Aseffa A, Bedru A, Yamuah L, et al. Safety of a trivalent meningococcal ACW135 vaccine among young children in Ethiopia. 2007 Sep 3;25 Suppl 1:A79-82. doi: 10.1016/j.vaccine.2007.04.046. Epub 2007 May 4. PMID: 17548138

Partnership and Collaboration

The Armauer Hansen Research Institute (AHRI) works with national, international and local partners and collaborators to advance high-quality biomedical and public health research. These relationships range from long-term strategic partnerships to project-specific scientific collaborations.

In- country Partners/Collaborators

International Partner/collaborators

Global Research Networks & Consortia

• EDCTP-supported research consortia

• WHO-coordinated research networks
• One Health and genomics research initiatives

Investigators and Study team

Picture	Full Name	Research Interest	Position/Rank	Telephone	E-mail address
	Adamu Bayissa Kiltu	Drugs and vaccine Clinical Trials	Senior Researcher /MD, MPH/	+251929041898	adamubayissa@ahri.gov.et
	Kassa Haile	Clinical trial, drug/device trial	Senior Researcher /M.D, MPH/	+251911396555	Kassa.haile@ahri.gov.et
	Hawult Taye Adane	Epidemiology, Trials Methods,	Senior Researcher /MPH, PHD/	+251911535973	hawultachew@gmail.com
	Tigist Adnew Getaneh	Oxygen therapy, pediatrics health, vaccine research	Researcher, /MD, pediatrician/	+251922736330	tigist.adnew@ahri.gov.et
	Sileshi Belew Yohannis	Bioanalytical (BE/BA), Clinical Pharmacology, Pharmaceutical analysis	Senior Researcher, PhD	+251904067994	sbphar2009@gmail.com
	Mekonnen Teferi Mekonnen	Products development, Bioequivalence & Clinical pharmacology, Pharmacovigillance	Researcher /DVM, MPharm/	+251911103233	mekonnen.teferi@ahri.gov.et
	Tadeye Abeje	Clinical Research	Researcher /MD, MPH/	+251912055473	tadeyeal@gmail.com
	Daniel Legese Achalu	Pharmacoepidemiological Researches	Researcher, Pharmacy Coordinator /B.pharm, MBA, MSc/	+251912750932	danigateline@gmail.com
	Muluye Shimeles Getahun	CRA and project management	Quality manager, Clinical monitor /BSc, MSc/	+251 911368499	muluye.shemeles@ahri.gov.et
	Netsanet Aragaw Tegegne	Clinical trial in infectious disease	Study Coordinator /BSc Nurse, MPH/	+251911357189	netsuhe2014@gmail.com
	Edilawit Mesfin Getachew	Infectious diseases epidemiology, Field Vaccine effectiveness Research	Associate Researcher /MD/	+251912287825	edmesfin2017@gmail.com
	Bethlehem Solomon	Clinical and implementation research on infectious diseases	Medical Researcher /MD, MSc/	+251925868781	betysolmn@gmail.com
	Hiwot Asmerom	Clinical Trial Infectious Disease	Study Coordinator, /BSc Nurse, MPH/	+251911483571	asmeromhiwot5@gmail.com
	Melat Gebremedihen Teklemariam	Research ethics on drug and vaccine trials, implementation study	Study Coordinator /BSc, MPH)	+251936960547	melatgebremedhin5@gmail.com
	Anatia Kifle	Drug and vaccine clinical trials, Non- communicable disease	Associate Researcher /MD, MSc./	+251912494318	kifleanatia@gmail.com
	Tahitawit Mulatu	Drug and vaccine clinical trials, Infectious disease	Associate Researcher /MD, MSc./	+251983312115	Tahitawitmula2@gmail.com
	Firehiwot Birhanu Gebremedhin	Non-infectious diseases	Researcher associate /MD, MPH/	0913561509	frehiwotbirhanu92@gmail.com
	Tsuruy Hagos Mesfin	Vaccine Trials, Infectious diseases & AMR studies, Non-communicable diseases	Project coordinator /MD, MPH/	+251 966250599	tsuruy.mesfin@gmail.com
	Amanuel Lulu	Public Health, implementation Research	Associate researcher /MD/	+251924847334	amanuel.lulu1@gmail.com
	Aliyi Amano Genemo	Clinical Trial Operations, Ethical & Regulatory Frameworks	Associate Researcher /BPharm, MSc/	+251947407134	aliyiamanog@gmail.com
	Ermias Hundito Abebe	Drug development in infectious and non-infectious diseases	Research Assistant /BSc/	+251916303538	ermiashundito@yahoo.com
	Yemisrach Zewdie Seralegne	One health, ethics and bioethics	Associate Researcher II /B.A, M.A/	+251911154197	yemzewd@gmail.com
	Yajeb Melesse  Belay	Nutraceuticals	Associate Researcher /Bpharm, MSc/	+251911690947	yajebmelesse@yahoo.com
	Mikael Abraham Hailemariam	QA and Monitoring of Clinical Research, Trial Management	Quality Officer /BSc, MPH/	+251964003558/+251912758022	miki4se@yahoo.com
	Tseganesh Asefa Yifru	Public health, Oncology, Clinical trials, Nutrition	Associate researcher II / BSc, MSc/	+251922736330	tseganesh16@gmail.com
	Endalkachew Birhanu	Lab technology, Biochemistry, Metabolic disorder	Associate researcher /BSc, MSc/	0913186148	endalkalem16@gmail.com
	Muluken Akalu	Hematology, microbiology	Senior Lab Tech /BSc, MSc/	+251970220178	akalumulukan@gmail.com
	Kerat Ali	Public health,clinical and any health qualitative research	Researcher Assistant /BSc/	+251983755324	kerat23ali@gmail.com
	Muluemebet Hailu	Laboratory diagnostics, public health, and clinical trials	Researcher Assistant /BSc/	+251922859016	hailumulumebat@gmail.com
	Saron Naji Gebremariam	Bioequivalence study and Drug trial study	Pharmacist /BSc, MSc/	251920163383	saronnaji@gmail.com
	Kasahun Wale	Analytical research areas	Researcher II	+251915556289	kasahun322@gmail.com
	Asamene Embiale Taye	Bioequivalence and environmental toxicity	Senior researcher, Associate professor/ PHD/	+251922875429	yembiale2@gmail.com

CTD Ambitions & Collaboration Opportunities

• A National and Regional Center of Excellence in Clinical Trials and Bioequivalence Studies for standard practices and training
• Realize a semi-autonomous, regulatory-compliant, internationally recognized bioequivalence center offering full services for regulatory submissions and pharmaceutical R&D.
• Strong Research teams that can lead and support local innovation for clinical development of drugs, vaccines, biologicals, diagnostics and medical devices.
• Leverage clinical pharmacology expertise to support IND regulatory submissions for new molecules.
• Establish AHRI-affiliated trial sites nationwide across diverse medical specialties and patient cohorts.
• Broaden access to trials and bioequivalence studies through extensive local and international networks and partnerships.
• Contribute to CTN-ET’s growth as a key entity shaping Ethiopia’s clinical trials and bioequivalence ecosystem.
• Invest in tailored training programs and leadership that are recognized regionally, continentally, and internationally.

Participate in global initiatives for pandemic preparedness, strengthening local capacity in vaccine trials and beyond.

Graduate students

	Gemmechu Hasen	Bioequivalence studies, pharmacokinetic study,  antimicrobial resistance	Researcher II, PhD Fellow	+251916973323	gemmechuhasen2009@gmail.com
	Derso Furgassa	Clinical research	Assistant researcher II/BSc lab Tech/	+251941958591	dersoyek@gmail.com